This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ram, Z. Articles by Oldfield, E. H. Search for Related Content PubMed PubMed Citation Articles by Ram, Z. Articles by Oldfield, E. H.

Intrathecal Gene Therapy for Malignant Leptomeningeal Neoplasia¹

Surgical Neurology Branch, National Institutes of Neurological Disorders and Stroke [Z. R., S. W., E. M. O., J. J. V., E. H. O.], and Metabolism Branch, National Cancer Institute [R. M. B.], National Institutes of Health, Bethesda Maryland 20892, and Genetic Therapy, Inc., Gaithersburg, Maryland 20878 [Y. C., S. N. M.]

In meningeal carcinomatosis, retroviral vector-producer cells can be introduced into the thecal sac and circulate in the cerebrospinal fluid to reach malignant tumor cells in the leptomeninges, release vector particles, and selectively infect and transfer a gene of interest to these cells. Gene transfer experiments with the lacZ gene and in vitro retroviral titer measurements showed that retroviral vectors can survive in the cerebrospinal fluid, retain their infectivity, and successfully transduce tumor cells. To examine the potential of intrathecal gene therapy, we evaluated the antitumor efficacy of in situ transduction with the herpes simplex-thymidine kinase gene followed by ganciclovir therapy in a rat model of leptomeningeal neoplasia. Fischer rats were inoculated via a subarachnoid catheter implanted at the upper thoracic level, and thymidine kinase vector-producer cells were injected into the subarachnoid space the day of tumor inoculation. Seven days later, rats received ganciclovir for 14 days by daily i.p. injections (30 mg/kg/ml) or intrathecal injections (25 µg/kg or 600 µg/kg) for 14 days. To evaluate possible enhancement of tumor eradication by the ability of helper virus to package the vector in the cells and further extend gene transfer, additional rats received thymidine kinase vector-producer cells that had been previously coinfected with a replication-competent retrovirus (4070A). In all groups, control rats received i.p. or intrathecal saline injections.

Ganciclovir administration i.p. resulted in significant prolongation of survival in rats given injections of thymidine kinase vector-producer cells. Injection of producer cells coinfected with the 4070A retrovirus did not improve antitumor efficacy. Intrathecal administration of ganciclovir (low and high doses) did not extend survival; histological examination of the spinal cords showed elimination of the infiltrative tumor in the leptomeninges, but residual tumor mass was present at the inoculation site, consistent with limited penetration of topical ganciclovir into the tumor.

These results support the potential application of gene therapy using the thymidine kinase/ganciclovir approach for treatment of meningeal carcinomatosis.

¹ This work was supported in part by Genetic Therapy, Inc., through a cooperative research and development agreement.

² To whom requests for reprints should be addressed, at Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Building 10, Room 5D-37, 9000 Rockville Pike, Bethesda, MD 20892.

Received 9/29/93. Accepted 2/18/94.

This article has been cited by other articles:

				G. Coukos, A. Makrigiannakis, E. H. Kang, D. Caparelli, I. Benjamin, L. R. Kaiser, S. C. Rubin, S. M. Albelda, and K. L. Molnar-Kimber Use of Carrier Cells to Deliver a Replication-selective Herpes Simplex Virus-1 Mutant for the Intraperitoneal Therapy of Epithelial Ovarian Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1523 - 1537. [Abstract] [Full Text] [PDF]